ABEV3 erupted higher on May 5, gaining 15.3% in a single session after reporting Q1 2026 results — its biggest one-day move in recent memory — and the question now is whether the rally has left positioning and valuation stretched or simply caught up with a story the market had been underpricing.
The backdrop heading into the print was bearish sentiment building. Short interest had been climbing steadily through April, rising from near zero on April 15 to a local peak of 0.09% of the free float by April 17 before pressing on to 0.09% and then retreating modestly in the days ahead of the earnings release. That is a negligible absolute level — below 0.1% of the float — so crowding was never a genuine risk. But the directional signal matters: shorts were adding exposure into results and they got caught. In the week to May 5, short interest fell from 0.071% to 0.052% of the free float, a clear unwind. The ORTEX short score has been trending down all fortnight, easing from 31.0 to 28.5, reflecting steadily decreasing short pressure. Availability, measured against current short interest, remains loose at roughly 9% utilization — well off the 52-week high of 47% — meaning the lending market is fully relaxed and there is no squeeze dynamic at play.
Borrow costs tell a different side of the story. The cost to borrow nearly doubled in the week to April 28, jumping 128% to 1.65% APR from 0.73% — though that compares favourably to February levels above 5%. The spike coincided with the ramp in short interest, suggesting that demand for borrows was building ahead of Q1 results. With the short unwind now underway, the next read on CTB in coming days will show whether those elevated borrow rates ease as former bears return stock.
The Street's reaction was swift. Barclays maintained its Equal-Weight rating on May 6 but raised its price target — the new target is $3.50 in USD ADR terms (ABEV on NYSE), which maps to roughly R$19-20 at prevailing exchange rates and represents meaningful upside to the current Bovespa price of R$16.65. The analyst consensus mean target sits at R$15.53, marginally below the current price, suggesting the broader Street had not yet caught up with Tuesday's move. EPS momentum scores are supportive — the 30-day EPS momentum factor ranks in the 74th percentile and the 90-day in the 64th — while Q1 adjusted EPS of US$0.05 came in roughly in line with expectations. Revenue of US$4.27 billion missed the US$4.46 billion estimate, the one number likely to keep some analysts cautious on near-term re-rating.
Valuation has moved with the stock. The PE multiple has expanded to 15.5x from around 14.7x a month ago, and EV/EBITDA has risen to 7.8x — up roughly one turn versus both the prior week and the prior month. Price-to-book is 3.0x. None of these multiples look extreme for a franchise of this size and quality, but the one-day re-rating has removed the valuation cushion that existed before results. Among peers, parent company ABI gained 9.3% on the day and 10.3% for the week — a broad tailwind for global beverage names that reinforced the ABEV3 move. KOF added 5.3% on the day while HEIO and HEIA were notably more subdued, up just 2.4% and 2.0% respectively, hinting that the Brazil-specific earnings catalyst drove disproportionate returns here relative to the wider sector.
On the ownership side, the structure is stable. AB InBev holds 62.4% of shares, essentially unchanged, while BlackRock added 44.6 million shares in the most recent reporting period to reach a 2.2% stake. Vanguard, Wellington, and MFS all trimmed marginally or added small positions — routine flow, nothing that moves the story. The dividend data in the snapshot is stale, last updated December 2021, so no read is available on current yield or payout trends.
With Q2 results pencilled in for July 30, attention will shift to whether top-line revenue momentum can close the gap with consensus — the sales miss on Q1 is the one open item that the next print will need to answer.
See the live data behind this article on ORTEX.
Open ABEV3 on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
